Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years of age~* Clinical diagnosis of DVT or PE~Exclusion Criteria:~* Contraindications for enoxaparin or warfarin~* Active bleeding or high risk for serious bleeding~* Short life expectancy~* Uncontrolled high blood pressure~* Significantly impaired kidney or liver function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: ACTIVE_COMPARATOR): apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
- Enoxaparin + Warfarin (Type: EXPERIMENTAL): Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.

Based on this trial design, predict the completion outcome and termination type (if applicable).